CN104257955A - Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture - Google Patents
Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture Download PDFInfo
- Publication number
- CN104257955A CN104257955A CN201410457705.6A CN201410457705A CN104257955A CN 104257955 A CN104257955 A CN 104257955A CN 201410457705 A CN201410457705 A CN 201410457705A CN 104257955 A CN104257955 A CN 104257955A
- Authority
- CN
- China
- Prior art keywords
- mass parts
- ethanol
- extract
- arisaema amurense
- hepatoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound with anti-hepatoma activity and a production method of the traditional Chinese medicine compound. The compound is characterized by being particularly prepared from the following raw materials in parts by weight: 220-260 parts of arisaema amurense, 180-240 parts of rhizoma menispermi, 240-300 parts of elecampane and 260-300 parts of liquorice. The extraction method of the arisaema amurense extract comprises the following processes: ethanol reflux and extraction, petroleum ether extraction and the like. The compound has the efficacies of resolving hard lumps, resisting cancers and relieving tumors, promoting blood circulation to remove blood stasis, detoxifying and counteracting toxic substances, enhancing the immunity, and enhancing the digestive function, and the compound is provided for the first time as a clinical anti-hepatoma medicine.
Description
Technical field
The present invention relates to a kind of Chinese medicine compound compound of anti-hepatocarcinoma, more particularly, relate to a kind of compound Chinese medicinal preparation and production method thereof of the anti-hepatocarcinoma containing arisaema amurense Maxim.
Background technology
Hepatocarcinoma is common malignant tumor of liver, and Chinese mortality of liver cancer is 10.09/10 ten thousand people.Current operative treatment is still the main path of liver cancer treatment, answers early diagnosis to strive for performing the operation early.For the mid and late liver cancer patient losing surgical engine meeting, selectivity hepatic arterial infusion (TAI) is adopted to be clinical conventional treatment means.TAI is to be equal to or less than the dosage via arterial infusion medicine of intravenously administrable by conduit.Target cell local drug concentration can be made like this to improve and prolong drug and pathological changes time of contact, and reduce the total drug dose of whole body, reach the object improving curative effect and minimizing side effect.Mid and late liver cancer patient general body is weak, and General Symptoms is obvious, although regional perfusion decreases dosage, the side effect that chemotherapeutic is serious still produces harm to patient, even reduces life quality.In recent years, the effect of Chinese medicine first phase gentleness, slight side effect and definite curative effect become the pretty good selection medication of TAI gradually.
Arisaema amurense Maxim (A.amurense Maxim.) is Arisaema herbaceos perennial, mainly originates in Changbaishan area and other mountain area, Jilin Province, upper level, aboundresources in China.Arisaema amurense Maxim tuber energy drying dampness to eliminate phlegm recorded by document, wind-expelling pain-stopping, mass dissipating and swelling eliminating, and for pertinacious phlegm cough, wind disease is dizzy, apoplexy, facial hemiparalysis, hemiplegia, epilepsy, infantile convulsion, tetanus.Recent a lot of researchs have confirmed that Rhizoma Arisaematis has active anticancer.Zhang Heming etc. have described the apoptotic effect of Rhizoma Arisaematis ethanol extract induction people K562 in detail in " the apoptotic experimentation of Rhizoma Arisaematis alcohol extract induction people K562 " literary composition; Yang Zonghui etc. detail the apoptotic effect of Rhizoma Arisaematis extract induction Bel7402 SMMC-7721 in " experimentation of Rhizoma Arisaematis extract induction human hepatocarcinoma BEL-7402 apoptosis and mechanism thereof " literary composition.Correlational study has confirmed that Rhizoma Arisaematis has active anticancer.
Summary of the invention
The invention provides a kind of anti-hepatocarcinoma compound Chinese medicinal preparation and method thereof.
Compound Chinese medicinal preparation provided by the invention, is prepared by following raw material: the arisaema amurense Maxim of 220-260 mass parts, the Rhizoma Menispermi of 180-240 mass parts, the Radix Aucklandiae of 240-300 mass parts, the Radix Glycyrrhizae of 260-300 mass parts.
Compound Chinese medicinal preparation provided by the invention, specifically can be prepared by following raw material: the arisaema amurense Maxim of 240 mass parts, the Rhizoma Menispermi of 210 mass parts, the Radix Aucklandiae of 270 mass parts, the Radix Glycyrrhizae of 280 mass parts.
The preparation method of described compound preparation: the arisaema amurense Maxim of described mass parts is added alcohol reflux, reclaims ethanol, and evaporate to dryness redissolves, and adds petroleum ether extraction, and abandon petroleum ether and retain aqueous phase, evaporate to dryness obtains arisaema amurense Maxim extract.The Rhizoma Menispermi of above-mentioned mass parts, the Radix Aucklandiae and Radix Glycyrrhizae add alcohol reflux, reclaim ethanol evaporate to dryness and obtain extract; Extract obtained and above-mentioned arisaema amurense Maxim extract is mixed homogeneously, obtains described anticancer blending ingredients, can be used for making the pharmaceutical preparation such as tablet, capsule.
The method of described extraction arisaema amurense Maxim extract:
(1) alcohol extraction: 95% ethanol (W: V=1kg: 5L) adding 5 times in the arisaema amurense Maxim coarse powder of above-mentioned mass parts, hot reflux 4 times, reflux temperature is 65 DEG C; Filtered and recycled ethanol.
(2) ethanol is reclaimed in distilling under reduced pressure, and pressure is 0.1MPa, and temperature is 55 DEG C.
(3) redissolve: amount of water is about 8 times of extract dry weight.
(4) petroleum ether extraction: the oil adding equivalent.
(5) evaporate to dryness: distilling under reduced pressure, pressure is 0.1MPa, and temperature is 55 DEG C.
The method of described extraction Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae mixed extract:
(1) in the Rhizoma Menispermi of above-mentioned mass parts, the Radix Aucklandiae, Radix Glycyrrhizae coarse powder, add 95% ethanol (W: V=1kg: 6L) of 6 times, hot reflux 4 times, reflux temperature is 60 DEG C; Filtered and recycled ethanol.
(2) ethanol is reclaimed in distilling under reduced pressure, and pressure is 0.1MPa, and temperature is 55 DEG C; Evaporate to dryness obtains mixed extract.
Above-mentioned two kinds of extract mix homogeneously, can need according to use amount the oral drug preparation such as tablet, capsule making all size.
Arisaema amurense Maxim, Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae are carried out compound recipe and are used for Therapeutic cancer by the present invention, and are determined the ratio of various component by prescription screening, are propose first time.The present invention also protects the production method of this compound medicine.
Detailed description of the invention
Following embodiment is convenient to understand the present invention better, but does not limit the present invention.Experimental technique in following embodiment, if no special instructions, is conventional method; Without the temperature of specified otherwise, be room temperature.Test material used in following embodiment, if no special instructions, is and purchases available from routine biochemistry reagent shop.
Arisaema amurense Maxim, Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae: be purchased from full Pharmaceutical Co., Ltd of Haozhou city hundred; Ethanol: be purchased from Panjin City the 5th pharmaceutical factory.
The preparation of embodiment 1, arisaema amurense Maxim extract
1, alcohol extraction: add 12L 95% ethanol in 2.4kg arisaema amurense Maxim coarse powder, hot reflux 4 times, each 2 hours, reflux temperature is 65 DEG C; Filtered and recycled filtrate.
2, ethanol is reclaimed: ethanol is reclaimed in distilling under reduced pressure, and pressure is 0.1MPa, and temperature is 55 DEG C; Obtain extract 252g.
3, redissolve: add water 2L in extract, and extract is dissolved completely.
4, extract: the petroleum ether adding equivalent in above-mentioned solution, fully exquisite layering after mixing, abandon petroleum ether and retain aqueous phase.
5, evaporate to dryness: above-mentioned aqueous phase distilling under reduced pressure, pressure is 0.1MPa, and temperature is 55 DEG C; Until evaporate to dryness, final proper extract 180g.
Embodiment 2, Rhizoma Menispermi, the Radix Aucklandiae, the preparation of Radix Glycyrrhizae mixed extract
1, alcohol extraction: 2.1 kilograms of Rhizoma Menispermi coarse powder, 2.7 kilograms of Radix Aucklandiae coarse powder, 2.8 the mixing of Radix Glycyrrhizae coarse powder, add 45.6L 95% ethanol wherein, hot reflux 4 times, reflux temperature is 60 DEG C; Filtered and recycled filtrate.
2, evaporate to dryness: distilling under reduced pressure, pressure is 0.1MPa, and temperature is 55 DEG C, until evaporate to dryness, obtains 460g mixed extract.
Prepared by embodiment 3, Rhizoma Arisaematis compound capsule
Get the extract be worth according to the method for embodiment 1 and embodiment 2, obtain various test sample according to table 1 prescription.
Table 1 test sample capsule prescription
Take various composition according to table 1 prescription, fully mix, pour in 0# conventional capsule according to the fill amount of every 500mg by medicated powder, each sample each gets 400.
Embodiment 4: Rhizoma Arisaematis compound capsule is to mice transplanted tumor H
22tumor-inhibiting action
1, material
1.1 laboratory animals: Kunming mouse, cleaning grade, 20 ~ 23g, male and female half and half.Be purchased from Liaoning Medical University's Experimental Animal Center.Zoopery room temperature 20 ~ 24 DEG C.Relative humidity 40% ~ 60%, meets cleaning grade zoopery standard.
1.2 tumor strains: H22 cell strain is purchased from Bo Gu bio tech ltd, Shanghai, to go down to posterity preservation with seroperitoneum tumor form in Mice Body, every 7-9d goes down to posterity 1 time.
1.3 medicines: the test sample of embodiment 3 gained.
2, experimental technique
2.1 inoculations and grouping: the mouse peritoneal hydrops of the 7th day after aseptic aspiration goes down to posterity. add 4 times amount normal saline mixings, be inoculated in the right oxter of mice immediately, every Mus inoculum concentration is 0.2ml tumor liquid.Random inoculation 50, after inoculation, 24h is divided into 5 groups at random, often organizes 10.1st group is model group, and the 2nd group is blank group, and the 3rd group is treatment group, and the 4th group is contrast 1 group, and the 5th group is contrast 2 groups
2.2 medications: the 1st group of conventional raising, refuse any process; 2nd group gives test sample 4; 3rd group gives test sample 1, and the 4th group gives test sample 2, and the 5th group gives test sample 3, and 1 capsules once a day, gets to the greatest extent content gavage, successive administration 8 days.
2.3 tumour inhibiting rates calculate: after last administration, 24h takes off neck and puts to death mice and strip tumor tissue and weigh, and obtains tumour inhibiting rate: (the average tumor of model group weighs an administration group average tumor weight)/model group average tumor weight × 100%=tumour inhibiting rate according to following formula.
2.4 statistical analysis: continuous data represents with x ± s, each group difference compares with t inspection, adopts SPSS15.0 software to carry out statistical analysis, thinks that difference exists significant difference with P < 0.05.
3, experimental result: in table 2
The each test sample tumour inhibiting rate of table 2
Note: * compares P < 0.05 with model group; # compares P < 0.05 with treatment group
4, discuss
Experimental result shows, gained arisaema amurense Maxim compound capsule of the present invention transplants H to mice
22the tumour inhibiting rate of tumor is the highest, and curative effect is best.Although the simple Rhizoma Arisaematis extract does not add Rhizoma Menispermi, the Radix Aucklandiae and Radix Glycyrrhizae embody certain tumor killing effect yet, curative effect is effective not as compound preparation.Do not add arisaema amurense Maxim and only have Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae mixed extract sample almost without tumor suppression curative effect.Above-mentioned experimental result shows that compound preparation of the present invention can the growth of Tumor suppression, determined curative effect; And arisaema amurense Maxim plays a major role in formula.
Claims (6)
1. a herbal mixture mixture for anti-hepatocarcinoma, is characterized in that being made up of arisaema amurense Maxim, Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae.
2. medicinal mixture according to claim 1, can by the arisaema amurense Maxim of 220-260 mass parts, the Rhizoma Menispermi of 180-240 mass parts, and the Radix Aucklandiae of 240-300 mass parts, the Radix Glycyrrhizae of 260-300 mass parts is made.
3. medicinal mixture according to claim 2, can by the arisaema amurense Maxim of 240 mass parts, the Rhizoma Menispermi of 210 mass parts, and the Radix Aucklandiae of 270 mass parts, the Radix Glycyrrhizae of 280 mass parts is made.
4. produce the production method of medicinal mixture described in claim 1-3 for one kind, it is characterized in that obtaining arisaema amurense Maxim extract by alcohol reflux, decompression recycling ethanol, petroleum ether extraction, then and obtain through ethanol extraction Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae mixed extract fully mix.
5. production method according to claim 4, extract the method for arisaema amurense Maxim extract specifically:
(1) alcohol extraction: 95% ethanol (W: V=1kg: 5L) adding 5 times in the arisaema amurense Maxim coarse powder of respective quality part, hot reflux 4 times, reflux temperature is 65 DEG C, filtered and recycled ethanol;
(2) ethanol is reclaimed in distilling under reduced pressure, and pressure is 0.1MPa, and temperature is 55 DEG C;
(3) redissolve: amount of water is about 8 times of extract dry weight;
(4) petroleum ether extraction: the petroleum ether adding equivalent;
(5) evaporate to dryness: distilling under reduced pressure, pressure is 0.1MPa, and temperature is 55 DEG C.
6. production method according to claim 4, extract Rhizoma Menispermi, the Radix Aucklandiae, Radix Glycyrrhizae mixed extract method specifically:
(1) in the Rhizoma Menispermi of above-mentioned mass parts, the Radix Aucklandiae, Radix Glycyrrhizae coarse powder, add 95% ethanol (W: V=1kg: 6L) of 6 times, hot reflux 4 times, reflux temperature is 60 DEG C; Filtered and recycled ethanol;
(2) ethanol is reclaimed in distilling under reduced pressure, and pressure is 0.1MPa, and temperature is 55 DEG C; Evaporate to dryness obtains mixed extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410457705.6A CN104257955A (en) | 2014-09-10 | 2014-09-10 | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410457705.6A CN104257955A (en) | 2014-09-10 | 2014-09-10 | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104257955A true CN104257955A (en) | 2015-01-07 |
Family
ID=52149612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410457705.6A Pending CN104257955A (en) | 2014-09-10 | 2014-09-10 | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257955A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800474A (en) * | 2015-05-13 | 2015-07-29 | 齐齐哈尔医学院 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
| CN106511638A (en) * | 2016-12-30 | 2017-03-22 | 吉林大学 | Antitumor traditional Chinese medicine composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122230A (en) * | 1994-11-02 | 1996-05-15 | 成都新兴中医药研究所 | Compond sansheng pills |
| CN103285343A (en) * | 2013-04-17 | 2013-09-11 | 山东省立医院 | Medicine for treating liver cancer and preparation method thereof |
| CN103520360A (en) * | 2013-10-16 | 2014-01-22 | 中国海洋大学 | Chinese herbal compound preparation, and preparation method and application of Chinese herbal compound preparation |
| CN103830663A (en) * | 2014-01-24 | 2014-06-04 | 何成元 | A traditional Chinese medicine composition for treating liver cancer |
-
2014
- 2014-09-10 CN CN201410457705.6A patent/CN104257955A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122230A (en) * | 1994-11-02 | 1996-05-15 | 成都新兴中医药研究所 | Compond sansheng pills |
| CN103285343A (en) * | 2013-04-17 | 2013-09-11 | 山东省立医院 | Medicine for treating liver cancer and preparation method thereof |
| CN103520360A (en) * | 2013-10-16 | 2014-01-22 | 中国海洋大学 | Chinese herbal compound preparation, and preparation method and application of Chinese herbal compound preparation |
| CN103830663A (en) * | 2014-01-24 | 2014-06-04 | 何成元 | A traditional Chinese medicine composition for treating liver cancer |
Non-Patent Citations (2)
| Title |
|---|
| 李春娜等: ""东北天南星化学成分和药理作用研究进展"", 《中华中医药学会中药化学分会第九届学术年会论文集（第一册）》 * |
| 李杨等: ""天南星提取物的抗炎作用及机制研究"", 《大理学院学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800474A (en) * | 2015-05-13 | 2015-07-29 | 齐齐哈尔医学院 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
| CN104800474B (en) * | 2015-05-13 | 2018-02-06 | 齐齐哈尔医学院 | A kind of Chinese medicine composition for treating liver fibrosis and its preparation method and application |
| CN106511638A (en) * | 2016-12-30 | 2017-03-22 | 吉林大学 | Antitumor traditional Chinese medicine composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN102145158A (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN102145159A (en) | Ginger and elecampane composition, preparation method of ginger and elecampane composition and use of ginger and elecampane composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN101264311B (en) | Natural pharmaceutical composition, its preparation and its attenuation synergistic use in cancer radiotherapy and chemotherapy | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN102133385A (en) | Ginger and white pepper composition, preparation method thereof and application thereof to preparation of medicaments for attenuation and synergia in cancer radiochemotherapy | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN102772611A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102091312B (en) | Ginger and wild pepper composition and preparation method thereof, and application of ginger and wild pepper composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| CN104069194A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN103919819A (en) | Poria cocos natural composition and anti-cancer vomit-preventing application thereof | |
| CN1269522C (en) | Traditional Chinese medicine for treating cancer and its preparation method | |
| CN113384667B (en) | Pharmaceutical composition for preventing and treating liver injury and/or liver cancer and preparation method and application thereof | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN101015680B (en) | Use of F-Glucoside peptide in preparing medicine for treating tumour | |
| CN102133383B (en) | Ginger and fingered citron composition, preparation method thereof and application of ginger and fingered citron composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN102166337A (en) | Ginger and inula flower composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer | |
| CN102100836B (en) | Medicinal composition for treating tumors, preparation method thereof and application thereof | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150107 |